

PHARMACY POLICY STATEMENT

North Carolina Marketplace

DRUG NAME	Koselugo (selumetinib)
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Koselugo, approved by the FDA in 2020, is a kinase inhibitor indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). It works by targeting mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). MEK is a component of a pathway that is often activated in certain types of cancer. NF1 is a rare, progressive genetic

